研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

美国热疗和放射治疗相结合,用于临床前胶质母细胞瘤模型。

Combination of US hyperthermia and radiotherapy on a preclinical glioblastoma model.

发表日期:2024 Aug 27
作者: Gianni Durando, Federica Vurro, Fabio Saba, Aoife M Ivory, Raphaela de Melo Baesso, Piero Miloro, Antonello E Spinelli
来源: Disease Models & Mechanisms

摘要:

在这项工作中,研究了超声(US)热疗(HT)与放射治疗(RT)相结合的效果。将治疗应用于通过注射2×10 6 U87 luc细胞获得的GBM异种移植裸鼠模型。联合治疗组接受6 Gy和43°HT 8 min。超声场由闭环计算控制系统产生,该系统由中心频率为 3.57 MHz 的高强度聚焦超声 (HIFU) 换能器、功率放大器、函数发生器和 MATLAB 控制器组成。机械锥适配器设计用于在预定义的后焦距处使用 HIFU 光束。将两个热电偶放置在机械锥体和小鼠皮肤之间,以测量和控制 HT 治疗期间的温度。放射治疗采用专用的小动物图像引导放射治疗系统进行。使用卡尺进行的肿瘤体积测量显示,在治疗后长达 21 天,RT-HT 组相对于 RT 组或对照组具有良好的肿瘤控制。治疗后两周内,标准化(治疗前)肿瘤体积的平均值几乎等于 0.5,在处死时增加至 1.5。对照组和 HT 组在前两周显示出较高的值,约为 1.5,在随访期结束时显示为 3.5。我们的结论是,使用 HT 作为放射增敏剂可以改善胶质母细胞瘤的治疗效果。© 2024。作者。
In this work the effect of combining ultrasound (US) hyperthermia (HT) with radiotherapy (RT) was investigated. The treatment was applied to a GBM xenograft nude mouse model obtained by injecting 2 × 10 6 U87 luc+ cells. The combined treatment group received 6 Gy and HT at 43 ∘ for 8 min. The ultrasound field was generated by a closed-loop computationally controlled system, consisting of a High Intensity Focused Ultrasound (HIFU) transducer with centre frequency 3.57 MHz, a power amplifier, a function generator and a MATLAB controller. A mechanical cone adaptor has been designed to use the HIFU beam at a pre-defined post-focal distance. Two thermocouples were placed between the mechanical cone and the mice skin to measure and control the temperature during the HT treatment. Radiotherapy was carried out by using a dedicated small animal image guided radiotherapy system. Measurements of tumor volume performed with a caliper showed good tumor control for the RT-HT group with respect to the RT or control groups for up to 21 days after treatment. The mean value of the normalized (before therapy) tumor volume was almost equal to 0.5 for two weeks after treatment with an increase to 1.5 at sacrifice. The control and HT groups showed a higher value of about 1.5 during the first two weeks and 3.5 at the end of the follow-up period. We concluded that the use of HT as a radiosensitizer can improve the outcome for glioblastoma treatments.© 2024. The Author(s).